FDA approves first RSV vaccine, for adults 60 and older
The Food and Drug Administration on May 3 approved the first U.S. vaccine for respiratory syncytial virus, Arexvy by GlaxoSmithKline Biologicals, for use in individuals aged 60 and older.
“Older adults, in particular those with underlying health conditions, such as heart or lung disease or weakened immune systems, are at high risk for severe disease caused by RSV,” said Peter Marks, M.D., director of the FDA’s Center for Biologics Evaluation and Research. “Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening and reflects the FDA’s continued commitment to facilitating the development of safe and effective vaccines for use in the United States.”
Related News Articles
Headline
The Food and Drug Administration Sept. 29 released a proposed rule that would phase out over four years its general enforcement discretion approach for most…
News
As proposed yesterday by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention recommends that starting this fall…
Headline
The 5th Circuit Court of Appeals should reverse the Federal Trade Commission’s decision in Illumina Inc. v. FTC, “a paradigmatic example” of how the agency’s…
Headline
As urged by the AHA, the U.S. Supreme Court today unanimously reversed a 9th Circuit decision that impliedly stripped federal district courts of…
Headline
The White House today released additional details related to President Biden’s budget request for fiscal year 2024. The main budget documents were released…
Headline
The U.S. District Court for the District of Connecticut this week largely dismissed a lawsuit alleging that Yale New Haven Hospital violated its fiduciary…